Gerresheimer (GXI) Stock Overview
Provides medicine packaging, drug delivery devices, and solutions in Germany and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
GXI Community Fair Values
Create NarrativeSee what 22 others think this stock is worth. Follow their fair value or set your own to get alerts.
Gerresheimer AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €26.64 |
| 52 Week High | €85.95 |
| 52 Week Low | €26.02 |
| Beta | 0.76 |
| 1 Month Change | -38.48% |
| 3 Month Change | -43.49% |
| 1 Year Change | -68.60% |
| 3 Year Change | -54.85% |
| 5 Year Change | -69.45% |
| Change since IPO | -30.53% |
Recent News & Updates
Recent updates
Why We're Not Concerned About Gerresheimer AG's (ETR:GXI) Share Price
Sep 18
Here's Why Gerresheimer (ETR:GXI) Is Weighed Down By Its Debt Load
Jul 31Positive Sentiment Still Eludes Gerresheimer AG (ETR:GXI) Following 28% Share Price Slump
Jun 18Shareholders May Be Wary Of Increasing Gerresheimer AG's (ETR:GXI) CEO Compensation Package
May 30Gerresheimer (ETR:GXI) Is Due To Pay A Dividend Of €1.25
May 29Is There Now An Opportunity In Gerresheimer AG (ETR:GXI)?
May 14Gerresheimer (ETR:GXI) Is Due To Pay A Dividend Of €1.25
Apr 24Earnings Troubles May Signal Larger Issues for Gerresheimer (ETR:GXI) Shareholders
Apr 19It's Down 32% But Gerresheimer AG (ETR:GXI) Could Be Riskier Than It Looks
Apr 11Gerresheimer (ETR:GXI) Will Pay A Dividend Of €1.25
Apr 10Gerresheimer (ETR:GXI) Has Announced A Dividend Of €1.25
Mar 05Why Investors Shouldn't Be Surprised By Gerresheimer AG's (ETR:GXI) 25% Share Price Surge
Feb 25
Expansion Into High-Margin Biologics And Devices Indicates Strong Future Prospects
Strategic expansion into high-margin segments like drug delivery systems and ready-to-use vials could enhance revenue and EBITDA margins significantly.Is Gerresheimer (ETR:GXI) Using Too Much Debt?
Jan 12Is It Time To Consider Buying Gerresheimer AG (ETR:GXI)?
Dec 26Gerresheimer AG Just Missed EPS By 14%: Here's What Analysts Think Will Happen Next
Oct 03Is Gerresheimer (ETR:GXI) Using Too Much Debt?
Sep 29Gerresheimer AG's (ETR:GXI) Share Price Matching Investor Opinion
Aug 31Shareholders Will Most Likely Find Gerresheimer AG's (ETR:GXI) CEO Compensation Acceptable
May 30Gerresheimer AG's (ETR:GXI) Share Price Matching Investor Opinion
May 22An Intrinsic Calculation For Gerresheimer AG (ETR:GXI) Suggests It's 40% Undervalued
May 03Analysts Are Updating Their Gerresheimer AG (ETR:GXI) Estimates After Its First-Quarter Results
Apr 14Gerresheimer's (ETR:GXI) Dividend Will Be €1.25
Apr 12Gerresheimer (ETR:GXI) Has A Somewhat Strained Balance Sheet
Apr 10Gerresheimer (ETR:GXI) Has Announced A Dividend Of €1.25
Feb 25Investors Still Waiting For A Pull Back In Gerresheimer AG (ETR:GXI)
Feb 10At €92.85, Is Gerresheimer AG (ETR:GXI) Worth Looking At Closely?
Jan 23Are Investors Undervaluing Gerresheimer AG (ETR:GXI) By 28%?
Jan 03Is Gerresheimer (ETR:GXI) Using Too Much Debt?
Dec 15When Should You Buy Gerresheimer AG (ETR:GXI)?
Oct 19An Intrinsic Calculation For Gerresheimer AG (ETR:GXI) Suggests It's 42% Undervalued
Oct 01Is Gerresheimer (ETR:GXI) Using Too Much Debt?
Aug 26Shareholder Returns
| GXI | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -7.4% | 4.0% | -1.4% |
| 1Y | -68.6% | -23.5% | 9.6% |
Return vs Industry: GXI underperformed the German Life Sciences industry which returned -23.5% over the past year.
Return vs Market: GXI underperformed the German Market which returned 9.6% over the past year.
Price Volatility
| GXI volatility | |
|---|---|
| GXI Average Weekly Movement | 8.2% |
| Life Sciences Industry Average Movement | 7.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 12.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: GXI's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: GXI's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1864 | 13,535 | Dietmar Siemssen | www.gerresheimer.com |
Gerresheimer AG, together with its subsidiaries, provides medicine packaging, drug delivery devices, and solutions in Germany and internationally. The company operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. It offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, and containers, bottles, caps, closures, applicators, and accessories; development, industrialization and contract manufacturing of drug delivery programs; project and quality management; and drug delivery devices, including inhalers, injection/auto injectors, and pen injectors.
Gerresheimer AG Fundamentals Summary
| GXI fundamental statistics | |
|---|---|
| Market cap | €920.15m |
| Earnings (TTM) | €23.35m |
| Revenue (TTM) | €2.25b |
Is GXI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GXI income statement (TTM) | |
|---|---|
| Revenue | €2.25b |
| Cost of Revenue | €1.65b |
| Gross Profit | €605.15m |
| Other Expenses | €581.80m |
| Earnings | €23.35m |
Last Reported Earnings
Aug 31, 2025
Next Earnings Date
Feb 26, 2026
| Earnings per share (EPS) | 0.68 |
| Gross Margin | 26.89% |
| Net Profit Margin | 1.04% |
| Debt/Equity Ratio | 155.5% |
How did GXI perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/17 17:23 |
| End of Day Share Price | 2025/10/17 00:00 |
| Earnings | 2025/08/31 |
| Annual Earnings | 2024/11/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Gerresheimer AG is covered by 34 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pallav Mittal | Barclays |
| Gaurav Jain | Barclays |
| Samuel England | Berenberg |